Cancer
Malignant Rectal Neoplasm
CI-CAN-00008012Explore in graph →
Top-level388 active trials1 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00008012Explore in graph →
Variants & evidence
8 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR2 Overexpression1 | ||||||||
| (prognostic) | Rectal CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID6459FGFR2 over-expression was observed in 75.9 % (n = 107)of the 141 eligible patients and was correlated with perineural invasion (P = 0.005) and inferior tumor regression grading (TRG) (P = 0.009). On u… (full text at CIViC) PMID 26831663 · Yoon et al., 2016 · Open in CIViC | civic |
| KRAS Exon 2 Mutation1 | ||||||||
| (prognostic) | Rectal CarcinomaALIAS | Prognostic | B | Does Not Support Poor Outcome | 2 | accepted | EID4052This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for KRAS exon 2 mutations (l… (full text at CIViC) PMID 19903786 · He et al., 2009 · Open in CIViC | civic |
| High1 | ||||||||
| Dostarlimab | Rectal CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID1236847 patients with locally advanced rectal cancer were treated with dostarlimab. 41 completed treatment and achieved a clinical complete response. No patients experienced local or distant disease recurr… (full text at CIViC) | civic |
| MTHFR A222V1 | ||||||||
| Fluorouracil | Rectal CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1757Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and 3.25 times more likely not to experience relapse (95%… (full text at CIViC) PMID 26693073 · Nikas et al., 2015 · Open in CIViC | civic |
| NOTCH3 Overexpression1 | ||||||||
| Tarextumab | Rectal CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7002Finally, treatment of CRC cells with anti-Notch2/3 antibody increased Numb protein while significantly reducing formation of spheroids in both MICOL-14tum cells and primary tumor cultures. This novel … (full text at CIViC) PMID 24525742 · Pastò et al., 2014 · Open in CIViC | civic |
| PIK3CA E545K1 | ||||||||
| (prognostic) | Rectal CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 2 | accepted | EID2106This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA exon 10 and 21 mu… (full text at CIViC) PMID 19903786 · He et al., 2009 · Open in CIViC | civic |
| PIK3CA Exon 10 Mutation + PIK3CA Exon 21 Mutation1 | ||||||||
| (prognostic) | Rectal CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID7220This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA mutations in exon… (full text at CIViC) PMID 19903786 · He et al., 2009 · Open in CIViC | civic |
| High1 | ||||||||
| (prognostic) | Rectal AdenocarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID13211This study evaluated genomic biomarkers associated with treatment response and clinical outcomes in patients with locally advanced rectal adenocarcinoma (LARC) treated with neoadjuvant chemoradiation … (full text at CIViC) PMID 37260182 · Lee et al., 2023 · Open in CIViC | civic |
Data updated 11 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.